Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.
AUTOR(ES)
Brown, I G
RESUMO
The effect of adding nebulised ipratropium bromide to bronchodilator treatment was studied in 20 patients with severe chronic airflow limitation. Maintenance theophylline with or without a steroid preparation was continued and comparison made between placebo, nebulised salbutamol, and a combination of nebulised salbutamol and ipratropium. Although the mean FEV1 values showed the combination to produce a small but significant increase in peak bronchodilatation over the effect of salbutamol alone, there were eight patients in whom no clinically useful improvement occurred. The remaining 12 patients did obtain clinically useful improvement in the magnitude or the duration of bronchodilatation (or both) as a result of the added ipratropium. The conclusion is that individual patients with chronic airflow limitation responded to the addition of nebulised ipratropium bromide in a variable way. Patients who could obtain additional benefit from ipratropium need to be identified by an appropriate reversibility study before its inclusion in their bronchodilator treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=459782Documentos Relacionados
- Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation.
- Controlled trial of respiratory muscle training in chronic airflow limitation.
- Controlled trial of respiratory muscle training in chronic airflow limitation.
- Inspiratory and skeletal muscle strength and endurance and diaphragmatic activation in patients with chronic airflow limitation.
- Effect of oral prednisolone on response to salbutamol and ipratropium bromide aerosols in patients with chronic airflow obstruction.
